Since this was a 10 patient study I don't think results are 'better' than Sparsentan. I see them as remarkably similar. Sparsentan is already in Ph3 with first readout due within 9 months (covid permitting). I'm expecting DXB's next trial results to be much the same in terms of % reduction.
These results warrant an increase in the SP. Maybe not a spectacular one sadly.
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-47
-
- There are more pages in this discussion • 240 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 21052 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |